Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-37 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-37b (IL-1F7) Recombinant Protein HEK293 Expressed, High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL-37 Products |
| Gene Delivery | IL-37 Lentivirus Particles Full-length ORF for stable overexpression in mammalian cells. |
View IL-37 Products |
| Benchmark Ab | Anti-IL-37 Reference Antibody Recombinant monoclonal for ELISA/Western validation. |
View IL-37 Products |
| Validator | IL-37 siRNA Set Gene-specific knockdown for specificity controls. |
View IL-37 Products |
| Co-Receptor | IL-18Rα (IL-18R1) ECD-Fc Protein Required for functional IL-37 receptor complex assembly. |
View IL-18R1 Products |
| Accessory Receptor | SIGIRR (IL-1R8) ECD Protein Co-receptor for anti-inflammatory signaling validation. |
View SIGIRR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Specificity (IL-37a vs b vs d) | Full-length IL-37b (active form) and domain-truncated variants available; Sequence Verified by Mass Spec |
| Species Cross-reactivity (Human/Cyno/Mouse) | Ortholog proteins for Human, Cynomolgus, and Mouse with >95% purity; Theoretical MW confirmed |
| Receptor Complex Assembly & Validation (Heterodimer IL-18Rα/SIGIRR) | Matched IL-18Rα and SIGIRR ECD proteins for SPR/BLI binary and ternary interaction assays; HEK293 expressed for native glycosylation |
| Pro-form vs. Mature Active Form Differentiation | Sequence-verified mature IL-37 (cleaved equivalent) to bypass caspase-1 processing requirements in vitro |
| False Positives & Lack of Controls | Validated IL-37 siRNA, neutralizing antibodies, and endotoxin-controlled (<1EU/ug) antigens for specificity and background prevention |
Live IL-37 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development of IL-37 (also known as IL-1F7) is rapidly accelerating as its unique role as a fundamental inhibitor of innate immunity and inflammation is increasingly understood. Unlike pro-inflammatory IL-1 family members, IL-37 acts as a broad-spectrum anti-inflammatory brake by binding to IL-18Rα and recruiting the decoy receptor SIGIRR (IL-1R8). Current R&D is shifting from traditional anti-cytokine antibodies to recombinant agonist biologics, with first-generation IL-37-Fc fusion proteins advancing toward the clinic for autoimmune indications. The next wave of R&D is targeting combination therapies with IL-1β or IL-18 blockade, engineered variants with enhanced receptor selectivity, and targeted delivery systems to overcome the natural instability of the wild-type cytokine. Gene therapy and cell therapy approaches are also gaining traction for localized inflammation and metabolic syndromes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Cytokine / Fc Fusion | Biotechs in Autoimmune Space | SLE, Rheumatoid Arthritis, GvHD | Receptor Binding Assay (Need IL-18Rα/SIGIRR heterodimer proteins and endotoxin-free antigens) |
| Gene Therapy (Lentiviral) | Academic / Gene Therapy Cos | IBD, Cytokine Storm | Overexpression Validation (Need high-titer IL-37 Lentivirus and stable cell line tools) |
| Agonistic Antibodies (anti-IL18R1/SIGIRR) | Various Biopharma | SLE, Metabolic Inflammation | Receptor Dimerization Assays (Need correctly folded IL18R1 and SIGIRR ECD proteins) |
| Bi-Specific Agonists | Immunology Focused Biotechs | Rheumatoid Arthritis, IBD | Cross-reactivity Panel (Need Human/Cyno/Mouse orthologs and isoform-selective reagents) |